Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
8.1
4.9
Journals
IJMS
Special Issues
Strategies to Fight Metabolic Diseases
ijms-logo
Submit to Special Issue Submit Abstract to Special Issue Review for IJMS Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Strategies to Fight Metabolic Diseases

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: 20 October 2024 | Viewed by 4263

Special Issue Editors

Prof. Dr. Carlos Palmeira

E-Mail Website
Guest Editor
Department of Life Sciences and Center for Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal
Interests: liver; muscle; adipose tissue; ischemia/reperfusion; mitochondria; steatosis; mitochondrial signaling and bioenergetics; mitochondrial dynamics; mitohormesis
Special Issues, Collections and Topics in MDPI journals
Dr. Anabela P. Rolo

E-Mail Website
Guest Editor
Center for Neurosciences and Cell Biology, University of Coimbra, Coimbra, Portugal
Interests: PCR; electrophoresis; gene expression; molecular biology; cell biology; biochemistry; signal transduction; Western blot; oxidative stress; signaling pathways; liver diseases; mitochondria bioenergetics; mitochondria isolation; liver mitochondria
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Metabolic diseases comprise a collection of disorders that occur together and increase the risk of developing type 2 diabetes, cardiovascular diseases (stroke or heart disease), cancer and neurodegeneration. The causes of metabolic syndrome are complex and poorly understood (the role of nutrition and physical activity, the role of single-cell transcriptomics, gut microbiota, epigenetics), and the precise pathogenetic mechanisms unifying all of its components are still unknown.

Metabolic strategies, such as exercise, fasting and carbohydrate-restricted diets, aim to restore mitochondrial function. Lifestyle changes are fundamental to the management of metabolic diseases, but sometimes pharmacological interventions are needed.

In this Special Issue, taking into account all the information that exists regarding metabolic disorders, the objective is to present/discuss potential pharmacological and lifestyle strategies that contribute to the management of these diseases that are so prevalent in today's society. Submissions of molecular-level research related to metabolic diseases and their treatment are welcome.

The topics of the Special Issue will include, but are not limited to, the following:

  • Pathogenesis of metabolic diseases;
  • Drug development: Developing new drugs to intervene with metabolic pathways and molecular signaling pathways;
  • RNA interference (RNAi) therapy: Utilizing small interfering RNA (siRNA) or similar molecules to inhibit or silence the expression of specific genes;
  • Antioxidants: Reducing oxidative damage to cells and molecules by antioxidants to combat the development of metabolic diseases.

Prof. Dr. Carlos Palmeira
Dr. Anabela P. Rolo
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • metabolic diseases
  • RNA interference (RNAi) therapy
  • metabolic strategies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

28 pages, 3497 KiB  
Review
Metabolic Derangement of Essential Transition Metals and Potential Antioxidant Therapies
by Adriana Fontes, Adrian T. Jauch, Judith Sailer, Jonas Engler, Anabela Marisa Azul and Hans Zischka
Int. J. Mol. Sci. 2024, 25(14), 7880; https://doi.org/10.3390/ijms25147880 - 18 Jul 2024
Viewed by 911
Abstract
Essential transition metals have key roles in oxygen transport, neurotransmitter synthesis, nucleic acid repair, cellular structure maintenance and stability, oxidative phosphorylation, and metabolism. The balance between metal deficiency and excess is typically ensured by several extracellular and intracellular mechanisms involved in uptake, distribution, [...] Read more.
Essential transition metals have key roles in oxygen transport, neurotransmitter synthesis, nucleic acid repair, cellular structure maintenance and stability, oxidative phosphorylation, and metabolism. The balance between metal deficiency and excess is typically ensured by several extracellular and intracellular mechanisms involved in uptake, distribution, and excretion. However, provoked by either intrinsic or extrinsic factors, excess iron, zinc, copper, or manganese can lead to cellular damage upon chronic or acute exposure, frequently attributed to oxidative stress. Intracellularly, mitochondria are the organelles that require the tightest control concerning reactive oxygen species production, which inevitably leaves them to be one of the most vulnerable targets of metal toxicity. Current therapies to counteract metal overload are focused on chelators, which often cause secondary effects decreasing patients’ quality of life. New therapeutic options based on synthetic or natural antioxidants have proven positive effects against metal intoxication. In this review, we briefly address the cellular metabolism of transition metals, consequences of their overload, and current therapies, followed by their potential role in inducing oxidative stress and remedies thereof. Full article
(This article belongs to the Special Issue Strategies to Fight Metabolic Diseases)
►▼ Show Figures

Figure 1

44 pages, 7493 KiB  
Review
Metabolic Dysfunction–Associated Steatotic Liver Disease: From Pathogenesis to Current Therapeutic Options
by Piero Portincasa, Mohamad Khalil, Laura Mahdi, Valeria Perniola, Valeria Idone, Annarita Graziani, Gyorgy Baffy and Agostino Di Ciaula
Int. J. Mol. Sci. 2024, 25(11), 5640; https://doi.org/10.3390/ijms25115640 - 22 May 2024
Cited by 5 | Viewed by 2914
Abstract
The epidemiological burden of liver steatosis associated with metabolic diseases is continuously growing worldwide and in all age classes. This condition generates possible progression of liver damage (i.e., inflammation, fibrosis, cirrhosis, hepatocellular carcinoma) but also independently increases the risk of cardio-metabolic diseases and [...] Read more.
The epidemiological burden of liver steatosis associated with metabolic diseases is continuously growing worldwide and in all age classes. This condition generates possible progression of liver damage (i.e., inflammation, fibrosis, cirrhosis, hepatocellular carcinoma) but also independently increases the risk of cardio-metabolic diseases and cancer. In recent years, the terminological evolution from “nonalcoholic fatty liver disease” (NAFLD) to “metabolic dysfunction-associated fatty liver disease” (MAFLD) and, finally, “metabolic dysfunction-associated steatotic liver disease” (MASLD) has been paralleled by increased knowledge of mechanisms linking local (i.e., hepatic) and systemic pathogenic pathways. As a consequence, the need for an appropriate classification of individual phenotypes has been oriented to the investigation of innovative therapeutic tools. Besides the well-known role for lifestyle change, a number of pharmacological approaches have been explored, ranging from antidiabetic drugs to agonists acting on the gut–liver axis and at a systemic level (mainly farnesoid X receptor (FXR) agonists, PPAR agonists, thyroid hormone receptor agonists), anti-fibrotic and anti-inflammatory agents. The intrinsically complex pathophysiological history of MASLD makes the selection of a single effective treatment a major challenge, so far. In this evolving scenario, the cooperation between different stakeholders (including subjects at risk, health professionals, and pharmaceutical industries) could significantly improve the management of disease and the implementation of primary and secondary prevention measures. The high healthcare burden associated with MASLD makes the search for new, effective, and safe drugs a major pressing need, together with an accurate characterization of individual phenotypes. Recent and promising advances indicate that we may soon enter the era of precise and personalized therapy for MASLD/MASH. Full article
(This article belongs to the Special Issue Strategies to Fight Metabolic Diseases)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop